AXDX Accelerate Diagnostics Inc

Price (delayed)

$1.79

Market cap

$142.19M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.07

Enterprise value

$247.34M

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC ...

Highlights
Accelerate Diagnostics's EPS has increased by 25% YoY and by 15% from the previous quarter
The company's net income rose by 17% YoY and by 13% QoQ
AXDX's equity has shrunk by 62% QoQ but it is up by 14% YoY
AXDX's debt is down by 22% YoY but it is up by 7% QoQ
The gross profit has shrunk by 111% YoY and by 25% QoQ
The gross margin has shrunk by 110% YoY and by 22% QoQ

Key stats

What are the main financial stats of AXDX
Market
Shares outstanding
79.44M
Market cap
$142.19M
Enterprise value
$247.34M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
9.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.24
Earnings
Revenue
$12.22M
EBIT
-$55.23M
EBITDA
-$52.76M
Free cash flow
-$47.6M
Per share
EPS
-$1.07
Free cash flow per share
-$0.7
Book value per share
-$0.84
Revenue per share
$0.18
TBVPS
$1.04
Balance sheet
Total assets
$70.36M
Total liabilities
$127.13M
Debt
$118.81M
Equity
-$56.78M
Working capital
$52.9M
Liquidity
Debt to equity
-2.09
Current ratio
7.44
Quick ratio
6.39
Net debt/EBITDA
-1.99
Margins
EBITDA margin
-431.7%
Gross margin
-3.9%
Net margin
-553.5%
Operating margin
-551.7%
Efficiency
Return on assets
-82.4%
Return on equity
N/A
Return on invested capital
-33.4%
Return on capital employed
-88.9%
Return on sales
-451.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AXDX stock price

How has the Accelerate Diagnostics stock price performed over time
Intraday
-15.96%
1 week
26.95%
1 month
52.99%
1 year
-74.61%
YTD
-65.71%
QTD
80.32%

Financial performance

How have Accelerate Diagnostics's revenue and profit performed over time
Revenue
$12.22M
Gross profit
-$477,000
Operating income
-$67.43M
Net income
-$67.65M
Gross margin
-3.9%
Net margin
-553.5%
The gross profit has shrunk by 111% YoY and by 25% QoQ
The gross margin has shrunk by 110% YoY and by 22% QoQ
AXDX's net margin is up by 23% YoY and by 16% QoQ
The company's net income rose by 17% YoY and by 13% QoQ

Growth

What is Accelerate Diagnostics's growth rate over time

Valuation

What is Accelerate Diagnostics stock price valuation
P/E
N/A
P/B
N/A
P/S
9.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.24
Accelerate Diagnostics's EPS has increased by 25% YoY and by 15% from the previous quarter
AXDX's equity has shrunk by 62% QoQ but it is up by 14% YoY
AXDX's price to sales (P/S) is 92% less than its 5-year quarterly average of 142.9 and 56% less than its last 4 quarters average of 26.8
The revenue has grown by 8% year-on-year and by 3.7% since the previous quarter

Efficiency

How efficient is Accelerate Diagnostics business performance
Accelerate Diagnostics's ROS has increased by 21% YoY and by 14% from the previous quarter
Accelerate Diagnostics's ROA has increased by 7% from the previous quarter but it has decreased by 2.9% YoY
Accelerate Diagnostics's return on invested capital has increased by 7% QoQ but it has decreased by 4.4% YoY

Dividends

What is AXDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AXDX.

Financial health

How did Accelerate Diagnostics financials performed over time
The company's total assets is 45% lower than its total liabilities
The quick ratio fell by 33% QoQ and by 31% YoY
The company's current ratio fell by 33% YoY and by 30% QoQ
AXDX's equity has shrunk by 62% QoQ but it is up by 14% YoY
Accelerate Diagnostics's debt to equity has increased by 34% from the previous quarter and by 9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.